Seres Therapeutics Stock Current Valuation
| MCRB Stock | USD 0.77 0.04 5.48% |
Valuation analysis of Seres Therapeutics helps investors to measure Seres Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of November 24, 2024, Enterprise Value Over EBITDA is expected to decline to -3.26. In addition to that, Enterprise Value Multiple is expected to decline to -3.26. Fundamental drivers impacting Seres Therapeutics' valuation include:
Price Book 5.4864 | Enterprise Value 158 M | Enterprise Value Ebitda (2.07) | Price Sales 1.0388 | Enterprise Value Revenue 1.2509 |
Undervalued
Today
Please note that Seres Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Seres Therapeutics is based on 3 months time horizon. Increasing Seres Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Seres Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seres Stock. However, Seres Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.77 | Real 3.01 | Target 9.83 | Hype 0.77 | Naive 0.83 |
The real value of Seres Stock, also known as its intrinsic value, is the underlying worth of Seres Therapeutics Company, which is reflected in its stock price. It is based on Seres Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Seres Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Seres Therapeutics helps investors to forecast how Seres stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seres Therapeutics more accurately as focusing exclusively on Seres Therapeutics' fundamentals will not take into account other important factors: Seres Therapeutics Company Current Valuation Analysis
Seres Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Seres Therapeutics Current Valuation | 158.02 M |
Most of Seres Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Seres Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Seres Therapeutics is extremely important. It helps to project a fair market value of Seres Stock properly, considering its historical fundamentals such as Current Valuation. Since Seres Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Seres Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Seres Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Seres Current Valuation Historical Pattern
Today, most investors in Seres Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Seres Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Seres Therapeutics current valuation as a starting point in their analysis.
Seres Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Seres Therapeutics has a Current Valuation of 158.02 M. This is 98.9% lower than that of the Biotechnology sector and 96.6% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.05% higher than that of the company.
Seres Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in current valuation category among its peers.
Seres Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Seres Therapeutics from analyzing Seres Therapeutics' financial statements. These drivers represent accounts that assess Seres Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Seres Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 410.2M | 184.2M | 763.9M | 605.2M | 179.2M | 170.2M | |
| Enterprise Value | 383.1M | 105.6M | 633.1M | 604.8M | 265.2M | 251.9M |
Seres Fundamentals
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 158.02 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Shares Owned By Insiders | 13.19 % | ||||
| Shares Owned By Institutions | 37.56 % | ||||
| Number Of Shares Shorted | 17.85 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 5.49 X | ||||
| Price To Sales | 1.04 X | ||||
| Revenue | 126.33 M | ||||
| Gross Profit | (165.79 M) | ||||
| EBITDA | (85.43 M) | ||||
| Net Income | (113.72 M) | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 213.94 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (117.35 M) | ||||
| Short Ratio | 5.75 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Price To Earnings To Growth | (0.11) X | ||||
| Target Price | 3.87 | ||||
| Number Of Employees | 233 | ||||
| Beta | 2.05 | ||||
| Market Capitalization | 131.23 M | ||||
| Total Asset | 358.6 M | ||||
| Retained Earnings | (978.24 M) | ||||
| Working Capital | 76.75 M | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
| Net Asset | 358.6 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.